Back to journals
Academic Journal

American Journal of Psychiatry

25 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 25 psychedelic papers Blossom tracks from American Journal of Psychiatry line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does American Journal of Psychiatry carry?

Sourced

Tracked papers by publication year; 3 earlier papers published before 2012. Click a year for the running total.

6papers published in 2025

+500% vs 2024

24 published by 2025

Browse papers→

Don't read as the journal's total output: only the 25 of 25 tracked psychedelic papers from American Journal of Psychiatry with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does American Journal of Psychiatry publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
21
Safety & Risk Management
8
Suicidality
7
Addiction & Substance Use
6
PTSD
4
Adolescents
3
Public Health, Prevention & Behaviour Change
3
Anxiety Disorders
2
Other
14

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does American Journal of Psychiatry cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ketamine
16
Psilocybin
6
Esketamine
4
LSD
2
Mescaline
1
DMT
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

American Journal of Psychiatry has 25 tracked papers indexed in Blossom (1952–2026) from 221 authors, most often covering Ketamine, Psilocybin and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Safety & Risk Management.

Published Papers

Open Accessindividual

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial

This randomised, double-blind, placebo-controlled trial (n=50) tested low-dose sublingual buprenorphine after ketamine in adults with major depressive disorder and suicidal thoughts. Buprenorphine led to a greater and longer-lasting reduction in suicidal ideation than placebo, while depression scores were similar and no serious treatment-related side effects occurred.

Published
Journal
American Journal of Psychiatry
Authors
Tucciarone, J. M., Bandeira, I. D., Blasey, C., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., Bernert, R., DeBattista, C., Truong, H., Rodriguez, C. I., Heifets, B. D., Schatzberg, A. F.
Paywallindividual

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval

This real-world safety analysis of esketamine in the United States (n=58,483 patients, 1,486,213 treatment sessions over 58 months) found that sedation, dissociation, and increased blood pressure occurred in 34.7%, 41.0%, and 0.9% of sessions respectively, with serious adverse events in <0.1-0.18% of sessions, suicide rates lower than background rates, and 210 cases of abuse/misuse reported, confirming the established safety profile with no new safety signals identified.

Published
Journal
American Journal of Psychiatry
Authors
Sanacora, G., Ahmed, M., Brown, B., Cabrera, P., Doherty, T., Himedan, M., Kern, D. M., Lim, L., Lopena, O., Naranjo, R. R., Nuamah, I., Sarayani, A., Turkoz, I., Bowrey, H. E.
Open Accessindividual

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression

This secondary analysis of an RCT (n=59) investigates the impact of psilocybin-assisted therapy (PAT) and escitalopram (SSRI) on responsiveness to emotional stimuli in patients with moderate-to-severe major depressive disorder over a 6-week trial period. Responses to emotional faces were reduced in the SSRI group, not the psilocybin group at the follow-up.

Published
Journal
American Journal of Psychiatry
Authors
Wall, M. B., Demetriou, L., Giribaldi, B., Roseman, L., Ertl, N., Erritzoe, D., Nutt, D. J., Carhart-Harris, R. L.
Paywallmeta

Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis

This systematic review and meta-analysis (s=87; 2025) finds esketamine's efficacy as an adjunctive therapy for treatment-resistant depression (TRD) to be modest (effect size 0.15-0.23) and comparable to atypical antipsychotics, with no significant effect on suicidality. The review raises concerns about esketamine's abuse potential and unknown long-term effects. It also highlights regulatory issues, including deaths and emerging suicidality during clinical trials.

Published
Journal
American Journal of Psychiatry
Authors
Fountoulakis, K. N., Saitis, A., Schatzberg, A. F.
Open Accessindividual

Compass Psychological Support Model for COMP360 Psilocybin Treatment of Serious Mental Health Conditions

This article describes the Compass Psychological Support Model (CPSM) used to support participants with treatment-resistant depression undergoing investigational psilocybin treatment. The CPSM aims to ensure a safe and meaningful psychedelic experience, complemented by therapist training, mentoring, and fidelity assessment to maintain delivery quality and consistency.

Published
Journal
American Journal of Psychiatry
Authors
Kirlic, N., Lennard-Jones, M., Atli, M., Malievskaia, E., Modlin, N. L., Peck, S. K., Gaillard, R., Goodwin, G. M., Koelpin, D.
Open Accessindividual

Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial

This secondary of a Phase II study (n=84) investigates the effects of psilocybin-assisted therapy (PAT) on personality traits in alcohol use disorder (AUD). Psilocybin (2x, 25-40mg/70kg; n=44) significantly reduced neuroticism and increased extraversion and openness compared to placebo (diphenhydramine, n=40). Decreased impulsiveness correlated with lower alcohol consumption post-treatment, suggesting PAT may normalize abnormal personality traits in AUD.

Published
Journal
American Journal of Psychiatry
Authors
Pagni, B. A., Zeifman, R. J., Mennenga, S. E., Carrithers, B. M., Goldway, N., Bhatt, S. R., O'Donnell, K., Ross, S., Bogenschutz, M. P.

Quick Facts

Papers Indexed
25
h-Index
405
Open Access
No
Publisher
American Psychiatric Association
Country
United States
Website
Visit